Tags

Type your tag names separated by a space and hit enter

Tegaserod treatment for IBS: a model of indirect costs.
Am J Manag Care. 2005 Apr; 11(1 Suppl):S43-50.AJ

Abstract

Irritable bowel syndrome (IBS) has been associated with substantial time lost from work (absenteeism) and reduced productivity at work (presenteeism), which are the indirect costs of illness. This article presents a productivity model demonstrating the indirect costs associated with IBS and the reduction in those costs for a cohort of female employees hypothetically treated with tegaserod, a new selective serotonin (5-hydroxytryptamine [5-HT]) type 4 (5-HT4) receptor agonist, which is approved by the US Food and Drug Administration for treating women with IBS-C. The model is based on economic and epidemiologic published literature and clinical trial results. In this model, tegaserod treatment resulted in 1882 dollars in avoided lost productivity per treated female employee. Considering only the benefits of decreased work loss and the costs of medical therapy, the model predicts a benefit/cost ratio of 3.75 in the base case. From an employer's perspective, medical therapy for IBS with tegaserod is cost-effective under a series of assumptions for the treatment of women with IBS with constipation.

Authors+Show Affiliations

Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15926763

Citation

Smith, Dean G., et al. "Tegaserod Treatment for IBS: a Model of Indirect Costs." The American Journal of Managed Care, vol. 11, no. 1 Suppl, 2005, pp. S43-50.
Smith DG, Barghout V, Kahler KH. Tegaserod treatment for IBS: a model of indirect costs. Am J Manag Care. 2005;11(1 Suppl):S43-50.
Smith, D. G., Barghout, V., & Kahler, K. H. (2005). Tegaserod treatment for IBS: a model of indirect costs. The American Journal of Managed Care, 11(1 Suppl), S43-50.
Smith DG, Barghout V, Kahler KH. Tegaserod Treatment for IBS: a Model of Indirect Costs. Am J Manag Care. 2005;11(1 Suppl):S43-50. PubMed PMID: 15926763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tegaserod treatment for IBS: a model of indirect costs. AU - Smith,Dean G, AU - Barghout,Victoria, AU - Kahler,Kristijan H, PY - 2005/6/2/pubmed PY - 2005/6/10/medline PY - 2005/6/2/entrez SP - S43 EP - 50 JF - The American journal of managed care JO - Am J Manag Care VL - 11 IS - 1 Suppl N2 - Irritable bowel syndrome (IBS) has been associated with substantial time lost from work (absenteeism) and reduced productivity at work (presenteeism), which are the indirect costs of illness. This article presents a productivity model demonstrating the indirect costs associated with IBS and the reduction in those costs for a cohort of female employees hypothetically treated with tegaserod, a new selective serotonin (5-hydroxytryptamine [5-HT]) type 4 (5-HT4) receptor agonist, which is approved by the US Food and Drug Administration for treating women with IBS-C. The model is based on economic and epidemiologic published literature and clinical trial results. In this model, tegaserod treatment resulted in 1882 dollars in avoided lost productivity per treated female employee. Considering only the benefits of decreased work loss and the costs of medical therapy, the model predicts a benefit/cost ratio of 3.75 in the base case. From an employer's perspective, medical therapy for IBS with tegaserod is cost-effective under a series of assumptions for the treatment of women with IBS with constipation. SN - 1088-0224 UR - https://www.unboundmedicine.com/medline/citation/15926763/Tegaserod_treatment_for_IBS:_a_model_of_indirect_costs_ L2 - https://www.ajmc.com/pubMed.php?pii=2837 DB - PRIME DP - Unbound Medicine ER -